Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals

Respiratory Research

Volumn 9, Issue , 2008, Pages

  Sandström, Caroline S ^a   Novoradovskaya, Natalia ^b   Cilio, Corrado M ^a   Piitulainen, Eeva ^a   Sveger, Tomas ^a   Janciauskiene, Sabina ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; ENDOTOXIN RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; METABOLISM; MONOCYTE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANTIGENS, CD14; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MONOCYTES; RECEPTORS, IMMUNOLOGIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 44849116002     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-9-34     Document Type: Article

References (35)

1. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol 2004, 172(7):4470-4479.
2. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993, 14(3):121-125. 10.1016/0167-5699(93)90212-4, 7682078.
3. Burgmann H, Winkler S, Locker GJ, Presterl E, Laczika K, Staudinger T, Knapp S, Thalhammer F, Wenisch C, Zedwitz-Liebenstein K, Frass M, Graninger W. Increased serum concentration of soluble CD14 is a prognostic marker in gram-positive sepsis. Clin Immunol Immunopathol 1996, 80(3 Pt 1):307-310. 10.1006/clin.1996.0128, 8811052.
4. Takashi Kusunoki SDW. Serum levels of soluble CD14 in allergic inflammation. Allergology International 1998, 47:271-278.
5. Liu S, Khemlani LS, Shapiro RA, Johnson ML, Liu K, Geller DA, Watkins SC, Goyert SM, Billiar TR. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect Immun 1998, 66(11):5089-5098. 108634, 9784508.
6. Vodovotz Y, Liu S, McCloskey C, Shapiro R, Green A, Billiar TR. The hepatocyte as a microbial product-responsive cell. J Endotoxin Res 2001, 7(5):365-373.
7. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991, 147(5):1567-1574.
8. Durieux JJ, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, Schmidt RE, Lupker J, Ferrara P, Ziegler-Heitbrock HW, et al. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol 1994, 24(9):2006-2012. 10.1002/eji.1830240911, 7522157.
9. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol 1994, 152(12):5868-5876.
10. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005, 11(4):225-229.
11. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001, 108(3):485-493. 209364, 11489942.
12. Rey Nores JE, Bensussan A, Vita N, Stelter F, Arias MA, Jones M, Lefort S, Borysiewicz LK, Ferrara P, Labeta MO. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999, 29(1):265-276. 10.1002/(SICI)1521-4141(199901)29:01<265::AID-IMMU265>3.0.CO;2-G, 9933108.
13. Le-Barillec K, Si-Tahar M, Balloy V, Chignard M. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J Clin Invest 1999, 103(7):1039-1046. 408261, 10194477, 10.1172/JCI5779.
14. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005, 365(9478):2225-2236. 10.1016/S0140-6736(05)66781-5, 15978931.
15. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003, 168(7):818-900. 10.1164/rccm.168.7.818, 14522813.
16. Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, Turino GM. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am J Respir Crit Care Med 1997, 156(1):68-74.
17. Hendrick SJ, Silverman AK, Solomon AR, Headington JT. Alpha 1-antitrypsin deficiency associated with panniculitis. J Am Acad Dermatol 1988, 18(4 Pt 1):684-692.
18. Mazodier P, Elzouki AN, Segelmark M, Eriksson S. Systemic necrotizing vasculitides in severe alpha1-antitrypsin deficiency. Qjm 1996, 89(8):599-611.
19. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002, 165(11):1494-1498. 10.1164/rccm.2109013, 12045122.
20. Nita IM, Serapinas D, Janciauskiene SM. alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol 2007, 39(6):1165-1176. 10.1016/j.biocel.2007.02.017, 17448722.
21. Laurell CB, Sveger T. Mass screening of newborn Swedish infants for alpha antitrypsin deficiency. Am J Hum Genet 1975, 27(2):213-217. 1762737, 1079113.
22. Bernspang E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med 2007, 101(9):1971-1976. 10.1016/j.rmed.2007.04.003, 17532199.
23. Janciauskiene S, Moraga F, Lindgren S. C-terminal fragment of alpha1-antitrypsin activates human monocytes to a pro-inflammatory state through interactions with the CD36 scavenger receptor and LDL receptor. Atherosclerosis 2001, 158(1):41-51. 10.1016/S0021-9150(00)00767-X, 11500173.
24. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966, 15(1):45-52. 10.1016/0003-2697(66)90246-6, 5959431.
25. Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. Eur Respir J 2001, 17(6):1105-1111. 10.1183/09031936.01.00067501, 11491151.
26. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998, 18(5):670-674.
27. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988, 138(2):327-336.
28. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978, 204(5):345-351.
29. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987, 80(5):1366-1374. 442392, 3500183, 10.1172/JCI113214.
30. Eriksson S, Alm R, Astedt B. Organ cultures of human fetal hepatocytes in the study of extra-and intracellular alpha1-antitrypsin. Biochim Biophys Acta 1978, 542(3):496-505.
31. Stelter F, Pfister M, Bernheiden M, Jack RS, Bufler P, Engelmann H, Schutt C. The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms. Eur J Biochem 1996, 236(2):457-464. 10.1111/j.1432-1033.1996.00457.x, 8612616.
32. Jeyaseelan S, Chu HW, Young SK, Freeman MW, Worthen GS. Distinct roles of pattern recognition receptors CD14 and Toll-like receptor 4 in acute lung injury. Infect Immun 2005, 73(3):1754-1763. 1064978, 15731076, 10.1128/IAI.73.3.1754-1763.2005.
33. Grunwald U, Kruger C, Schutt C. Endotoxin-neutralizing capacity of soluble CD14 is a highly conserved specific function. Circ Shock 1993, 39(3):220-225.
34. Tasaka S, Ishizaka A, Yamada W, Shimizu M, Koh H, Hasegawa N, Adachi Y, Yamaguchi K. Effect of CD14 blockade on endotoxin-induced acute lung injury in mice. Am J Respir Cell Mol Biol 2003, 29(2):252-258. 10.1165/rcmb.2002-0132OC, 12639839.
35. Brass DM, Hollingsworth JW, McElvania-Tekippe E, Garantziotis S, Hossain I, Schwartz DA. CD14 is an essential mediator of LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 2007, 293(1):L77-83. 10.1152/ajplung.00282.2006, 17384086.